US Patent 6,703,403: Ritonavir CYP3A4 Inhibition Claims, Expiration, and Patent Landscape

US Patent 6,703,403 covers the use of ritonavir to inhibit cytochrome P450, particularly CYP3A4, and to increase the exposure, pharmacokinetic performance, or blood concentration of coadministered drugs. The patent is no longer enforceable because its term expired in 2017. Its commercial importance was substantial historically because it provided an early patent position around ritonavir boosting of HIV protease inhibitors, especially saquinavir. It does not create current generic-entry protection for ritonavir-boosted products.

What does US Patent 6,703,403 protect?

US Patent 6,703,403 protects methods using ritonavir, or a pharmaceutically acceptable salt, as a pharmacokinetic enhancer by inhibiting drug metabolism through cytochrome P450 enzymes.

The claims fall into five functional groups:

Claim group	Principal subject matter	Key limitation
Claims 1-2	CYP inhibition	Ritonavir inhibits CYP3A4; claim 1 requires administration to a human, while claim 2 covers contacting the enzyme
Claims 3-38	Pharmacokinetic improvement	Ritonavir is coadministered with a CYP-metabolized drug
Claims 39-47	Combination treatment	A therapeutically effective combination of the metabolized drug and ritonavir is administered
Claims 48-83	Increased blood level	Ritonavir is used to raise the blood concentration of the coadministered drug
Claims 84-92	Increased blood level through combination	A combination of the drug and ritonavir is administered to increase blood levels

The patent's core inventive concept is not the ritonavir molecule itself. It is the use of ritonavir's CYP-inhibitory activity to increase exposure to another drug.

What compounds are named in the patent?

The claims identify a broad group of compounds, including:

Saquinavir
MK-639, the development code for indinavir
VX-478, the development code for amprenavir
AG1343, the development code for nelfinavir
A-77003 and A-80987
DMP-323
Cyclosporine
FK-506, tacrolimus
Rapamycin
Paclitaxel, identified as taxol
Docetaxel, identified as taxotere
Clarithromycin
Several investigational HIV protease inhibitors

The most commercially relevant named combination was ritonavir with saquinavir. Saquinavir was marketed as Invirase and Fortovase, while ritonavir was marketed as Norvir. Later HIV products used ritonavir and, subsequently, cobicistat as pharmacokinetic enhancers.

How broad are the independent claims?

The independent claims are broad in concept but differ materially in their required facts.

Claim 1: Human administration to inhibit CYP3A4

Claim 1 requires:

A human in need;
Administration of ritonavir or a pharmaceutically acceptable salt;
An amount effective to inhibit CYP3A4.

The claim is directed to a therapeutic method rather than a composition. It does not require administration with a second drug. A human administration of ritonavir for the purpose of inhibiting CYP3A4 could fall within the literal scope if the other claim elements were satisfied.

Claim 2: Direct enzyme-contact claim

Claim 2 covers contacting CYP3A4 with ritonavir in an effective amount. It is materially broader in setting because it does not require a human, treatment, or coadministration.

Its practical enforcement value against a commercial medicine would be limited. A laboratory assay or research-use activity might be more directly relevant than routine patient treatment. The claim also raises scope questions concerning what qualifies as "contacting" the enzyme and whether the accused activity is a patent-infringing use under 35 U.S.C. § 271.

Claims 3 and 21: Pharmacokinetic improvement

Claims 3 and 21 cover use of ritonavir to improve the pharmacokinetics of a drug metabolized by cytochrome P450 monooxygenase.

These claims are broader than claims expressly limited to CYP3A4. They require a pharmacokinetic result or objective, such as improved exposure, but do not necessarily require that CYP3A4 be the only relevant enzyme.

Claims 4-11 and 22-29 narrow the coadministered drug. Claims 12-20 and 30-38 narrow the enzyme to CYP3A4.

Claims 39 and 84: Combination claims

Claims 39 and 84 require administration of a therapeutically effective combination of:

The CYP3A4-metabolized drug; and
Ritonavir or a pharmaceutically acceptable salt.

These claims are narrower than a claim directed only to ritonavir administration because they require a combination treatment. They are potentially more relevant to fixed-dose or coadministered products than to ritonavir monotherapy.

Claims 48 and 66: Increased blood level

Claims 48 and 66 cover increasing the blood level of a CYP-metabolized drug by administering ritonavir.

These claims require a blood-level outcome rather than merely CYP inhibition. Claims 84-92 repeat this concept with an express CYP3A4 limitation and a combination-treatment requirement.

Which claims are strongest from an enforcement perspective?

The most commercially significant claim categories are the human-treatment claims involving:

Ritonavir;
A named HIV protease inhibitor;
CYP3A4 metabolism; and
Improved pharmacokinetics or increased blood concentration.

Claims 39, 44, 84, and 89 are particularly focused on combination treatment with saquinavir or a similar named drug. Their narrower scope could make validity easier to defend against certain prior-art references, but it also limits their application to specific products and treatment regimens.

Claims 1 and 3 are conceptually broader. Their vulnerability would likely focus on prior disclosures of ritonavir, known CYP inhibition, the pharmacokinetic interaction between ritonavir and other protease inhibitors, and whether the claimed result was adequately supported and nonobvious at the relevant filing date.

A claim chart should distinguish between:

Issue	Relevance
Ritonavir administered alone	Relevant to claims 1, 3, 21, 48, and 66
Ritonavir administered with another drug	Relevant to claims 3, 21, 39, 48, 66, and 84
CYP3A4 specifically involved	Required by claims 1, 12-20, 30-38, 39-47, 57-65, 75-83, and 84-92
Named coadministered drug	Required by the applicable dependent claim
Increased drug blood level	Required by claims 48-92
Human treatment	Required by most method claims, but not claim 2
Fixed-dose formulation	Not expressly required by the claims

When did US Patent 6,703,403 expire?

US Patent 6,703,403 issued on March 9, 2004. The patent's term expired in 2017 based on the applicable 20-year patent-term calculation from the relevant US filing and priority chain. Public patent databases identify the patent as expired. [1]

Event	Date or status
Patent issued	March 9, 2004
Patent term basis	20-year term under post-1995 US patent law
Projected expiration	2017
Current enforceability	Expired
Current Paragraph IV threat	None based solely on this patent
Current US blocking effect	None

The patent's expiration removes it as a current US infringement barrier. It does not invalidate other patents that may have covered ritonavir formulations, specific coformulations, manufacturing processes, or later pharmacokinetic-enhancer products.

What is the Orange Book status of US Patent 6,703,403?

The patent's relevance to the Orange Book depends on the NDA and product against which it was listed. A patent covering a method of using ritonavir with another drug may be listed against a drug product only if it satisfies FDA listing rules for approved-use patents. FDA Orange Book listings are product- and NDA-specific, not universal records of every patent that once related to a drug. [2]

Historically, patents associated with Norvir and other ritonavir products had regulatory significance. The expiration of US Patent 6,703,403 means that any historical Orange Book listing for the patent would no longer create an active patent barrier.

An ANDA applicant could previously have addressed an unexpired method patent through a Paragraph IV certification or a section viii statement, depending on the approved labeling and the use covered by the patent. Under the Hatch-Waxman framework, a Paragraph IV certification could trigger patent litigation and, in certain circumstances, a 30-month stay. [3]

Were there Paragraph IV challenges or litigation involving this patent?

The patent was directed to a use of ritonavir as a pharmacokinetic enhancer rather than to the basic ritonavir chemical structure. The principal litigation risk during its term would therefore have involved:

ANDA products containing ritonavir;
Generic versions of ritonavir used with HIV protease inhibitors;
Labeling that expressly instructed CYP3A4 inhibition or pharmacokinetic boosting;
Fixed-dose combinations or co-packaged products containing ritonavir and a named substrate;
Induced or contributory infringement theories involving prescriber and patient use.

No current Paragraph IV controversy can create an active exclusionary period under this expired patent. Any historical litigation or settlement would now be relevant mainly for provenance, damages, claim construction, or freedom-to-operate history.

An expired method patent can still matter in litigation over activity that occurred before expiration. The expiration date does not eliminate potential historical damages claims, subject to applicable limitations periods and other defenses.

What patent landscape surrounded ritonavir boosting?

The patent landscape had at least four distinct layers.

Ritonavir compound and composition patents

Early patents covered ritonavir as a chemical entity, stereochemical form, pharmaceutical composition, or manufacturing process. Those rights were separate from the CYP3A4-enhancement claims in US Patent 6,703,403.

Pharmacokinetic-enhancement patents

US Patent 6,703,403 occupied the pharmacokinetic-enhancement layer. It claimed use of ritonavir to inhibit CYP metabolism, improve exposure, and increase blood levels of coadministered drugs.

Later patents in the field could claim:

Specific dose ratios;
Particular protease inhibitors;
Fixed-dose combinations;
Specific treatment schedules;
Reduced-dose ritonavir regimens;
Formulations with defined release profiles;
Administration for hepatitis C or other indications.

Formulation patents

The asserted claims do not expressly require a tablet, capsule, liquid, suspension, coating, excipient, particle size, release profile, or dosage form. A later formulation patent could therefore provide independent protection even after the expiration of 6,703,403.

For example, a later patent might distinguish its claims through:

A particular ritonavir solid state;
A specific amorphous or crystalline form;
A defined dissolution profile;
A hot-melt extrusion or spray-drying process;
A tablet containing a specified polymer or surfactant;
A formulation that improves ritonavir bioavailability.

Such patents would not be automatically preempted by the expired method claims.

Cobicistat and newer enhancer patents

Cobicistat was developed as a selective pharmacokinetic enhancer without the antiviral activity of ritonavir. Its patent estate was distinct from the ritonavir estate and included composition, formulation, combination, and treatment patents.

A product using cobicistat instead of ritonavir would generally fall outside claims requiring ritonavir. A product using ritonavir and cobicistat could require a separate analysis of overlapping method, formulation, and combination claims.

How does ritonavir boosting compare with cobicistat boosting?

Issue	Ritonavir	Cobicistat
Primary role	Antiretroviral and pharmacokinetic enhancer	Pharmacokinetic enhancer
CYP3A inhibition	Yes	Yes
Antiviral activity	Yes	Limited or absent as a clinical antiviral
Early enhancer patent relevance	US 6,703,403 and related rights	Separate later patent families
Major combination use	Protease inhibitors	HIV integrase inhibitors and other agents
Patent risk today	6,703,403 expired; later rights may remain	Later formulation and combination patents may remain
Biosimilar relevance	None in the biologic sense	None in the biologic sense

Ritonavir and cobicistat are small molecules. Biosimilar analysis is therefore not applicable. The relevant competitive threat is generic substitution and alternative small-molecule enhancement, not biosimilar entry under the Public Health Service Act.

Which companies were relevant to the patent landscape?

The principal commercial entities associated with the relevant product and development landscape included:

Abbott Laboratories, the original developer and commercial sponsor associated with ritonavir and Norvir;
AbbVie, following Abbott's pharmaceutical separation;
Hoffmann-La Roche, associated with saquinavir and related HIV products;
Merck, associated with indinavir, corresponding to MK-639;
Vertex Pharmaceuticals, associated with amprenavir, corresponding to VX-478;
Agouron Pharmaceuticals and Warner-Lambert, associated with nelfinavir, corresponding to AG1343;
Gilead Sciences, Bristol-Myers Squibb, and other later developers of antiretroviral combination products.

The claimed list contains several development codes and experimental compounds. Many did not become commercial products. Their presence in the claims does not establish market exposure, regulatory approval, or continuing patent relevance.

What generic-entry risks exist after expiration?

The expiration of US Patent 6,703,403 removes a direct barrier to products that practice its claimed ritonavir-boosting methods. A generic or competitor could still face other barriers:

Active compound patents, if any remain in a relevant jurisdiction;
Formulation patents;
Polymorph or solid-form patents;
Manufacturing-process patents;
Combination-product patents;
Method-of-use patents covering a different disease or dosing regimen;
Regulatory exclusivity or labeling constraints;
Trade-secret manufacturing controls;
Market-access and supply-chain requirements.

For a conventional ritonavir product, the key current question is not whether US 6,703,403 remains enforceable. It is whether a separate unexpired patent covers the proposed formulation, manufacturing route, combination, or labeled use.

What is the geographic coverage of this patent?

US Patent 6,703,403 provides protection only in the United States. Foreign protection would depend on separately issued national patents or regional patents derived from the relevant application family.

The US expiration date does not determine the status of corresponding patents in:

Europe;
Canada;
Japan;
Australia;
China;
India;
Brazil;
Other jurisdictions.

A global freedom-to-operate assessment must treat each national patent separately because filing dates, patent-term adjustments, maintenance payments, opposition proceedings, supplementary protection certificates, and claim amendments can differ.

How strong is the patent estate today?

The patent estate represented by US Patent 6,703,403 has no current US exclusionary strength because the patent expired.

Its historical strength was higher in scenarios involving:

Ritonavir coadministered with saquinavir;
A regimen expressly intended to improve pharmacokinetics;
A product label identifying ritonavir as a CYP3A4 inhibitor;
Increased blood concentrations of a named protease inhibitor;
Fixed or coordinated administration of ritonavir and the substrate drug.

Its current value is primarily historical and analytical. It may assist in understanding the origin of ritonavir boosting, but it does not block a US generic launch on its own.

Key Takeaways

US Patent 6,703,403 claims methods using ritonavir to inhibit CYP450, especially CYP3A4.
The claims cover pharmacokinetic improvement, increased blood levels, and combination treatment with metabolized drugs.
Saquinavir is the most commercially important named drug in the claims.
Claims 1-2 address CYP3A4 inhibition directly; claims 3-92 focus on pharmacokinetic enhancement or increased blood concentration.
The patent issued on March 9, 2004, and expired in 2017.
The patent is no longer a current US barrier to generic or competing ritonavir products.
Formulation, manufacturing, compound, solid-form, and later combination patents must be analyzed separately.
Biosimilar risk is not applicable because ritonavir is a small molecule.
Foreign counterparts require separate country-by-country review.
Any historical Paragraph IV litigation or settlement may matter for past conduct, but cannot preserve an active exclusionary term after expiration.

FAQs

Does US Patent 6,703,403 cover ritonavir itself?

No. The patent claims methods of using ritonavir, principally to inhibit CYP3A4 or increase exposure to another drug. It is not a basic chemical compound patent on ritonavir.

Does the patent cover all CYP3A4 inhibitors?

No. The claims require ritonavir or a pharmaceutically acceptable salt of ritonavir. They do not cover unrelated CYP3A4 inhibitors such as cobicistat as such.

Can a generic use ritonavir as a pharmacokinetic enhancer today?

US Patent 6,703,403 does not prevent that because it expired in 2017. Other active patents, labeling restrictions, or regulatory requirements could still affect a particular product.

Are claims covering saquinavir and ritonavir still enforceable?

No, not under US Patent 6,703,403. The patent's term has expired. Separate patents covering saquinavir, ritonavir, formulations, or combination products require independent analysis.

Does the patent create biosimilar risk for HIV medicines?

No. Ritonavir and the listed protease inhibitors are small molecules regulated through the drug approval framework. Generic-drug and patent-certification issues, rather than biosimilar substitution, are the relevant market-entry framework.

References

United States Patent and Trademark Office. (2004). US Patent No. 6,703,403, Methods of inhibiting cytochrome P450 monooxygenase 3A4. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j); 35 U.S.C. §§ 156, 271(e).
U.S. Food and Drug Administration. (2024). Norvir (ritonavir) prescribing information. U.S. Department of Health and Human Services.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	225186	⤷ Start Trial
Austria	392895	⤷ Start Trial
Australia	6342096	⤷ Start Trial
Australia	722812	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,703,403

Summary for Patent: 6,703,403